Synergistic interaction between oncolytic viruses augments tumor killing

Molecular Therapy

Volumn 18, Issue 5, 2010, Pages 888-895

  Le Boeuf, Fabrice ^a,b   Diallo, Jean Simon ^a,b   McCart, J Andrea ^c   Thorne, Steve ^d   Falls, Theresa ^a,b   Stanford, Marianne ^a,b   Kanji, Femina ^a   Auer, Rebecca ^a   Brown, Christopher W ^b   Lichty, Brian D ^e   Parato, Kelley ^a   Atkins, Harold ^a,b   Kirn, David ^f   Bell, John C ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e MCMASTER UNIVERSITY   (Canada)

^f Jennerex Biotherapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; GENE PRODUCT; MEMBRANE PROTEIN; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; P14 FUSION ASSOCIATED SMALL TRANSMEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HT29; CELLULAR IMMUNITY; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG POTENTIATION; EX VIVO STUDY; FEASIBILITY STUDY; FEMALE; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; TUMOR CELL DESTRUCTION; VERO CELL; VIRUS RECOMBINANT; VIRUS RECOMBINATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; CERCOPITHECUS AETHIOPS; FEMALE; GENE THERAPY; GENETIC VECTORS; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VACCINIA VIRUS; VERO CELLS; VESICULOVIRUS;

VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 77951987824     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.44     Document Type: Article

References (32)

1. Bell, JC (2007). Oncolytic viruses: what's next? Curr Cancer Drug Targets 7:127-131.
2. Parato, KA, Senger, D, Forsyth, PA and Bell, JC (2005). Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5:965-976.
3. Crompton, AM and Kirn, DH (2007). From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr Cancer Drug Targets 7:133-139.
4. Russell, SJ and Peng, KW (2007). Viruses as anticancer drugs. Trends Pharmacol Sci 28:326-333.
5. Park, BH, Hwang, T, Liu, TC, Sze, DY, Kim, JS, Kwon, HC et al. (2008). Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 9:533-542.
6. Liu, TC, Hwang, T, Park, BH, Bell, J and Kirn, DH (2008). The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 16:1637-1642.
7. Kirn, D (2001). Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 8:89-98.
8. Kumar, S, Gao, L, Yeagy, B and Reid, T (2008). Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther 10:371-379.
9. McCart, JA, Ward, JM, Lee, J, Hu, Y, Alexander, HR, Libutti, SK et al. (2001). Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 61:8751-8757.
10. Parr, MJ, Manome, Y, Tanaka, T, Wen, P, Kufe, DW, Kaelin, WG Jr et al. (1997). Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med 3:1145-1149.
11. Thorne, SH, Hwang, TH, O'Gorman, WE, Bartlett, DL, Sei, S, Kanji, F et al. (2007). Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 117:3350-3358.
12. Symons, JA, Alcamí, A and Smith, GL (1995). Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81:551-560.
13. Alcamí, A and Smith, GL (1995). Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J Virol 69:4633-4639.
14. Colamonici, OR, Domanski, P, Sweitzer, SM, Larner, A and Buller, RM (1995). Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J Biol Chem 270:15974-15978.
15. Alcamí, A, Symons, JA and Smith, GL (2000). The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol 74:11230-11239.
16. Stojdl, DF, Lichty, B, Knowles, S, Marius, R, Atkins, H, Sonenberg, N et al. (2000). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6:821-825.
17. Stojdl, DF, Lichty, BD, tenOever, BR, Paterson, JM, Power, AT, Knowles, S et al. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4:263-275.
18. Lichty, BD, Stojdl, DF, Taylor, RA, Miller, L, Frenkel, I, Atkins, H et al. (2004). Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther 15:821-831.
19. Vancová, I, La Bonnardiere, C and Kontsek, P (1998). Vaccinia virus protein B18R inhibits the activity and cellular binding of the novel type interferon-delta. J Gen Virol 79 (Pt 7):1647-1649.
20. McCart, JA, Mehta, N, Scollard, D, Reilly, RM, Carrasquillo, JA, Tang, N et al. (2004). Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol Ther 10:553-561.
21. Naik, AM, Chalikonda, S, McCart, JA, Xu, H, Guo, ZS, Langham, G et al. (2006). Intravenous and isolated limb perfusion delivery of wild type and a tumor-selective
22. Breitbach, CJ, Paterson, JM, Lemay, CG, Falls, TJ, McGuire, A, Parato, KA et al. (2007). Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 15:1686-1693.
23. Moss, B and Earl, PL (2001). Overview of the vaccinia virus expression system. Curr Protoc Protein Sci Chapter 5: Unit5.11.
24. Moss, B (2006). Poxvirus entry and membrane fusion. Virology 344:48-54.
25. Clancy, EK and Duncan, R (2009). Reovirus FAST protein transmembrane domains function in a modular, primary sequence-independent manner to mediate cell-cell membrane fusion. J Virol 83:2941-2950.
26. Brown, CW, Stephenson, KB, Hanson, S, Kucharczyk, M, Duncan, R, Bell, JC et al. (2009). The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis. J Virol 83:552-561.
27. Thorne, SH and Contag, CH (2007). Combining immune cell and viral therapy for the treatment of cancer. Cell Mol Life Sci 64:1449-1451.
28. Aghi, M and Martuza, RL (2005). Oncolytic viral therapies - the clinical experience. Oncogene 24:7802-7816.
29. Liu, TC, Galanis, E and Kirn, D (2007). Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 4:101-117.
30. Liu, TC and Kirn, D (2007). Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res 67:429-432.
31. Power, AT, Wang, J, Falls, TJ, Paterson, JM, Parato, KA, Lichty, BD et al. (2007). Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther 15:123-130.
32. Chou, TC (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621-681.